In this study, we evaluated the expression levels of Trop-2 in cervical cancer tissues and in primary cervical cancer cell lines and also examined the preclinical anti-tumor activity of sacituzumab govitecan in Trop-2 positive primary cervical cancer models and xenografts. This evidence concerns the gene TACSTD2 and neoplasm.